Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)

SIMPLE SUMMARY: Adoptive cell transfer with chimeric antigen receptor (CAR)-modified immune effector cells (IECs) has quickly emerged as a paradigm-shifting approach for the management of B cell malignancies given its ability to induce high rates of remission. This is reflected by the regulatory app...

Descripción completa

Detalles Bibliográficos
Autores principales: Acharya, Utkarsh H., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761730/
https://www.ncbi.nlm.nih.gov/pubmed/33287224
http://dx.doi.org/10.3390/cancers12123617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761730/
https://www.ncbi.nlm.nih.gov/pubmed/33287224
http://dx.doi.org/10.3390/cancers12123617

Ejemplares similares